Outcome of Board Meeting

SUPRIYA LIFESCIENCE LTD. .. Creating true values that bind global health August 13, 2026 BSE Limited National Stock Exchange of India Limited Phiroze Jeejeebhoy Towers, Exchange Plaza, Plot no. C/1, G Block, Dalal Street, Bandra-Kurla Complex Mumbai- 400 001 Bandra (E), Mumbai - 400 051 S crip Code: 543434 NSE Symbol: SUPRIYA Dear Sir (s), Sub: Outcome of Board Meeting held on August 13, 2026 Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you that the Board of Directors of the Company at its Meeting held on Thursday, August 13, 2026, inter-alia considered and approved Unaudited Financial Results for the Quarter ended June 30, 2026. A copy of the same is enclosed along with the Limited Review Report of the Statutory Auditors thereon in terms of SEBI (LODR) Regulations, 2015. The Meeting of the Board of Directors of the Company commenced at 03:30 p.m. and concluded at 06.00 p.m. Kindly take the above information on your records. Thanking you, Yours faithfully, For Supriya Lifescience Limited Prachi Sathe Company Secretary & Compliance Officer Corporate office : 207/208, Udyog Bhavan, Sonawala Road, Goregaon (East), Mumbai – 400 063. Maharashtra, India. Tel: +91 22 40332727 / 66942507 Fax : +91 22 26860011 GSTIN: 27AALCS8686A1ZX CIN: L51900MH2008PLC180452 E-mail: supriya@supriyalifescience .com Website: www.supriyalifescience.com Factory : A-5/2, Lote Parshuram Industrial Area, M.I.D.C. Tal.– Khed, Dist. – Ratnagiri, Pin :415 722, Maharashtra, India. Tel: +91 2356 272299 Fax: +91 2356 272178 E-mail: factory@supriyalifescience.com GOVT. RECOGNISED EXPORT HOUSE KAKARIA AND ASSOCIATES LLP YOUR REF. CHARTERED ACCOUNTANTS OUR REF. : UJWAL K. KAKARIA B.Com.,B.L.,F.C.A. SUBHASH S. KOTADIA B.Com. (HONS.) F.C.A. JAIPRAKASH H. SHETHIYA B.Com., F.C.A. AMAR J. BHANUSHALI B.Com., D.T.M., F.C.A. VINAYAK P. BAFANA B.Com., F.C.A. Independent Auditor's Review Report on Quarterly Unaudited Financial Results of the Company Pursuant to the Regulation 33 and 52 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended. Board of Directors of Supriya Lifescience Limited, 1. We have reviewed the accompanying statement of unaudited financial results of Supriya Lifescience Limited ("the Company") for the quarter ended 30th June 2026, ("the Statement"), being submitted by the company pursuant to the requirements of Regulation 33 and 52 of the Securities and Exchange Board of India (Listing Obligation and Disclosure Requirements) Regulations, 2015 as amended (the "Listing regulations") 2. The Company's Management is responsible for the preparation of the Statement in accordance with the recognition and measw-ement principles laid down in Indian Accounting Standard 34, (Ind AS 34) "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 and 52 of the Listing Regulations. The Statement has been approved by the Company's Board of Directors. Our responsibility is to express a conclusion on the Statement based on our review. 3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting 802, Lotus Trade Centre, Near D.N. Nagar Meh·o Station, New Link Road, Andheri -West, Mumbai -400 053 Tel: 022 26744670. Email: mumbai;"' 1".ar=iriaassociates.com, Website: www.kakariaassociates.com , 1/I matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion. 4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards i.e. Ind AS prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued there under or by the Institute of Chartered Accountants of India and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and SEBI Circular dated 14th October, 2021 including the manner in which it is to be disclosed, or that it contains any material misstatement. Kakaria and Associates LLP Chartered Accountants. FRN: 104558W/ W100601 CA. Ujwal K. Kakaria Partner Membership No. - 035416 Place: -Mumbai Date: - I 31 o 8 / 2o 2 6 UDIN: - 2603.s-Lt \6 F=-'kKNOX l-166 2.. SUPRIYA LIFESClENCE LIMITED CIN No: L51900MH2008PLC180452 207/ 208, Udyog Bhauan, Sonawala Road, Gorogaon (East), Mumbai -400063. Te.I No.: +9122 40332727; E•maU: cs@)supriyaHfesdence.com; Website: www.suprlyalifesdence.com ('tlnmillionl Statement of Standalone Unaudited Financial Results for the Quarter Ended June 30 2026 Sr.No. Particulars Quarte.,. ended Quarter ended Quaner ended Year ended 30-06-2026 31-03-2026 30-06-2025 31-03-2026 Unaudited Audited Unaudited Audited Income I Revenue from Ooerations 1,897.47 2,765.28 1,450.74 8,278.75 II Other Income 26.48 34.78 26.74 114.87 Ill Total lnoome 1,923.95 2,800.0fi 1477.48 8,393.62 Expenses a) Cost of Materials Consumed 1,094.00 833.61 437.76 2,651.18 bl Purchase of Stock in Trade c) Change in inventories. of finished goods, work in progress & stock In trade. (530.15) 219.66 (120.04) (110.89) d} Emolovee benefit exoen.ses 284.90 248.17 226.88 966.80 e\ finance Cost 3.74 4.68 5.12 18.89 lfl Depreciation & amortisation expense 89.40 84.98 64.51 284.09 I~\ Other ex~nditure 574.14 487.67 389.13 1,831.18 IV Total Expenses 1,516.03 1,1178.77 1,003.36 5,641.25 V Profit/(loss) before E.ceptlonal Items & Tax (111 -IV) 407.92 921.29 474.12 2,752.37 VI Exceptional Items (4,581 vu Profit/floss) before Tax IV-Vil 407.92 921.29 474.12 2,747.79 VIII T"'Xb oen.se al CurrentTa,c 85.13 204.16 105.35 614.33 bl Deferred Tax 82.36 125.16) 20.87 42.26 IX Proflt/llossl for the oerlod from Continuin~ Ooeratlons (VII-VIIII 24-0.43 742.29 347.90 2,091.20 X Profit/(Lossl from d!.s.contlnued ooerations before tax XI Tax Experue of discontinued ooerc1tlons XII Profit/(Lossl from dlsc:on~nued operations after tax {X-XI) XIII Profil/(lossl for the period (IX+Xlll 24-0.43 742.29 347.90 2,091,20 XIV Other Comorehensive Income Am Item, that will not be reclassified to orofit or loss 8.65 0.55 (2.87) (1.33) (II) Income Tax relating to item.s that will not be reclasslfled to profit or loss (2.18) (0.14) 0.72 0.34 8 Ill Items that will be reclassified to profit or loss {ii) Income Tax relating to items that will be reclasslfied to profit or loss Total Comorehenslue Income for the oerlod IXlll+XIVI 246.90 742.70 345.75 2,090.21 XVI Earnlni:i:s 0er eaultv Share (for continuing os:>eratlonl: (11 Basic lln ,1 2.99 9.22 4.32 25.98 1121 Diluted !In ,1 2.99 9.22 4.32 25.98 XVII Earnlnlls oer eauitv Share lfor discontinued ocerationl: 11 Basic lln ,1 21 Diluted /In ,1 XVIII Earnings per equlty Share (for discontinued & continuing operations): !111 Basic fin ,1 2.99 9.22 4.32 25.98 (21 DIiuted !In ,1 2.99 9.22 4.32 25.98 See accompanying notes to the flnandal statements: Notes:- 1. The above unaudited standalone financial results of t [Showing first 8,000 characters — download PDF for full document]